Dermatological Toxicities Associated with Targeted Cancer Therapies: An In-Depth Analysis of Mechanisms, Treatment Strategies, and Existing Research Gaps—A Narrative Review - Takeaways - MDSpire

Dermatological Toxicities Associated with Targeted Cancer Therapies: An In-Depth Analysis of Mechanisms, Treatment Strategies, and Existing Research Gaps—A Narrative Review

  • By

  • Piotr Janicki

  • Anna Makowska

  • Anna Jakubczyk-Słabicka

  • Renata Zaucha

  • Wioletta Barańska-Rybak

  • Witold Owczarek

  • Magdalena Górska-Ponikowska

  • March 6, 2026

  • 0 min

Share

  • 1

    Targeted cancer therapies often lead to dermatological adverse events, affecting up to 90% of patients receiving these treatments.

  • 2

    Correct identification and management of cutaneous adverse events can optimize oncological treatment and minimize dose modifications.

  • 3

    Research on dermatological toxicities primarily focuses on immune checkpoint inhibitors, leaving other targeted therapies underrepresented.

  • 4

    Common skin toxicities associated with EGFR inhibitors include acneiform dermatitis, rash, and pruritus, impacting patient quality of life.

  • 5

    Combination therapies, such as BRAF and MEK inhibitors, generally result in fewer cutaneous adverse events compared to monotherapy.

Original Source(s)

Related Content